Theophylline · THEOPHYLLINE 450 mg/1 · Tablet, Extended Release · Oral · Teva Pharmaceuticals, Inc.
NDC 00480-3309-01 · 100 TABLET, EXTENDED RELEASE in 1 BOTTLE · ANDA · View full market →
18 companies supply this market — deep enough that no single failure threatens the supply. The price is down 21% over the past year, to $1.05 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Ajanta Pharma USA Inc. | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Ajanta Pharma USA Inc. | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Inc. | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Inc. | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Bionpharma Inc., | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Chartwell RX, LLC | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | THEOPHYLLINE ANHYDROUS 400 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | THEOPHYLLINE ANHYDROUS 600 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | THEOPHYLLINE ANHYDROUS 600 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | THEOPHYLLINE ANHYDROUS 400 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Harman Finochem Limited | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Harman Finochem Limited | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Leading Pharma, LLC | THEOPHYLLINE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Leading Pharma, LLC | THEOPHYLLINE 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| PD-Rx Pharmaceuticals, Inc. | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| PD-Rx Pharmaceuticals, Inc. | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Strides Pharma Science Limited | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Strides Pharma Science Limited | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals, Inc. | THEOPHYLLINE 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals, Inc. | THEOPHYLLINE 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Viona Pharmaceuticals Inc | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Viona Pharmaceuticals Inc | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | THEOPHYLLINE ANHYDROUS 450 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Brandywine Pharmaceuticals, LLC | THEOPHYLLINE ANHYDROUS 300 mg/1 | Jul 15, 2026 | Jul 29, 2026 |
| Brandywine Pharmaceuticals, LLC | THEOPHYLLINE ANHYDROUS 200 mg/1 | Jul 15, 2026 | Jul 29, 2026 |
| Brandywine Pharmaceuticals, LLC | THEOPHYLLINE ANHYDROUS 100 mg/1 | Jul 15, 2026 | Jul 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Theophylline — NDC 00480-3309-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00480330901.
Free to cite with attribution — see how the data is put together.